Greenwich Lifesciences Outlines Plans to Expand FLAMINGO-01 Trial Sites, Reduce Costs, Pursue Additional Patent Filings, and Advance Partnering Strategy for GLSI-100

Greenwich LifeSciences Inc. has outlined several key elements of its forward-looking strategy and planning. The company is continuing to focus on its Phase III FLAMINGO-01 clinical trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Future plans include expanding the trial by activating an additional 10 approved sites in 2026 and considering participation from more countries in the European Union, as well as exploring expansion into the United Kingdom and Canada. The company is also implementing cost reduction measures, such as moving more clinical trial operations in-house and ending the use of a contract research organization for U.S. and global management. Greenwich LifeSciences is maintaining its current financing strategy to support the ongoing burn rate and is actively seeking partnerships, including attending partnering conferences. The company is also working to strengthen its patent portfolio by filing patents for treating non-HLA-A*02 patients with GLSI-100.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9615883-en) on December 22, 2025, and is solely responsible for the information contained therein.